Verzenio adjuvant – pro
NCCN BINV 6, 2024 writes: ” Two years of adjuvant abemaciclib in combination with endocrine therapy can be considered in patients with HR+/HER2-negative, high-risk breast cancer (see eligibility criteria listed on (BINV-K). In patients eligible for both adjuvant olaparib and abemaciclib, the optimal choice of therapy and sequencing is not known.”
Priva Rastogi et al, Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. March 2024
Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O’Shaughnessy J, Rastogi P; monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020 Dec 1;38(34):3987-3998.
Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of hr+, her2-, nodepositive, high-risk, early breast cancer (monarchE). J Clin Oncol 2020;38:3987-3998. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32954927.
NCCN Breast Cancer 2024